Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
Abstract
We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia
(ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000
and 2009. Seventy-eight percent of patients received myeloablative conditioning and
52% underwent transplantation in second remission. Disease-free survival (DFS) was
24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than
expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic
relapse rather than transplant toxicity is the most important cause of treatment failure.
Advancements in leukemia control are especially needed for improvement in HCT outcomes
for DS-ALL.
Type
Journal articleSubject
CIBMTR Pediatric Cancer Working CommitteeHumans
Down Syndrome
Graft vs Host Disease
Genetic Predisposition to Disease
Recurrence
Tacrolimus
Cyclosporine
Antineoplastic Combined Chemotherapy Protocols
Immunosuppressive Agents
Myeloablative Agonists
Disease-Free Survival
Treatment Outcome
Transplantation Conditioning
Combined Modality Therapy
Salvage Therapy
Whole-Body Irradiation
Remission Induction
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation
Registries
Retrospective Studies
Adolescent
Adult
Child
Child, Preschool
Infant
Living Donors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kaplan-Meier Estimate
Allografts
Permalink
https://hdl.handle.net/10161/24654Published Version (Please cite this version)
10.1002/pbc.24918Publication Info
(2014). Outcome of transplantation for acute lymphoblastic leukemia in children with Down
syndrome. Pediatric blood & cancer, 61(6). pp. 1126-1128. 10.1002/pbc.24918. Retrieved from https://hdl.handle.net/10161/24654.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Joanne Kurtzberg
Jerome S. Harris Distinguished Professor of Pediatrics
Dr. Kurtzberg conducts both clinical and laboratory-based translational research
efforts, all involving various aspects of normal and malignant hematopoiesis. In the
laboratory, her early work focused on studies determining the mechanisms that regulate
the choice between the various pathways of differentiation available to the pluripotent
hematopoietic stem cell. Her laboratory established a CD7+ cell line, DU.528, capable
of multilineage differentiation as well as self-renewal, and subse
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info